KLF14, adipose dysfunction, insulin resistance and type 2 diabetes: from genetic discovery to biological mechanisms and translation.
Lead Research Organisation:
University of Oxford
Department Name: RDM OCDEM
Abstract
Type 2 diabetes is a major and growing cause of illness and death across the world. However, incomplete understanding of the processes involved in the development of this condition acts as a barrier to the development of better ways for treating and preventing the disease.
In the past few years, collaborative efforts in human genetic discovery have identified over fifty positions in the human genome where individual sequence variation is associated with risk of type 2 diabetes. In principle, each of these genetic "signals" holds important clues to the mechanisms that are responsible for the maintenance of normal metabolic health. However, in most of these regions, we have yet to define the specific genetic variants responsible for the signal, or the particular genes through which the effects on diabetes-risk are mediated. As a result, the pace of biological insights has lagged behind that of genetic discovery. A key challenge for the field is to develop strategies that enable genetic signals such as these to be mined for the biological clues they can provide.
We recently demonstrated that one of these diabetes signals maps near a gene named KLF14, and that this effect on risk of diabetes is driven by a reduced ability of insulin-sensitive tissues, including muscle and liver, to respond to insulin. We have also shown that, in fat tissue, the same variants near KLF14 have widespread effects on the levels of expression of a wide range of genes, including KLF14 itself. These data are consistent with a model whereby KLF14 acts as a major regulator of events in fat tissue, with these alterations in the levels of KLF14 leading, through as yet unspecified mechanisms, to peripheral insulin resistance and type 2 diabetes.
The overall aim of this research is to define the molecular, cellular and physiological mechanisms which are responsible for the relationship between KLF14 and type 2 diabetes. To do this, we will pursue a number of complementary research strategies which include studies of human genetics and physiology and cellular studies in fat cells.
More specifically, our work aims to:
(a) define the specific sequence variants that are responsible for all of these effects, and how they influence levels of KLF14 within fat cells;
(b) characterise the suite of genes that are turned on and off by KLF14, and understand the consequences of those secondary changes on the function of fat tissue; and
(c) understand how it is that these KLF14-dependent changes in fat tissue lead to changes in the ability of remote tissues (such as muscle and liver) to respond to insulin.
We expect that, by focusing on the role of KLF14 and the ways in which it leads to an increased risk of diabetes, we will gain valuable, generic insights into the mechanisms whereby events in fat have widespread metabolic effects in other tissues. An answer to this question would help us improve our understanding of the connections between obesity and diabetes, an issue of supreme importance given that much of the increase in diabetes prevalence around the world is driven by changes in the amount, distribution and function of fat.
The research provides an opportunity to capitalise on recent discoveries in human genetics to advance understanding of disease biology. In the application, we explain how the biological information generated by this project can be exploited in directly translational studies to define novel approaches for treating, preventing, diagnosing and monitoring type 2 diabetes.
In the past few years, collaborative efforts in human genetic discovery have identified over fifty positions in the human genome where individual sequence variation is associated with risk of type 2 diabetes. In principle, each of these genetic "signals" holds important clues to the mechanisms that are responsible for the maintenance of normal metabolic health. However, in most of these regions, we have yet to define the specific genetic variants responsible for the signal, or the particular genes through which the effects on diabetes-risk are mediated. As a result, the pace of biological insights has lagged behind that of genetic discovery. A key challenge for the field is to develop strategies that enable genetic signals such as these to be mined for the biological clues they can provide.
We recently demonstrated that one of these diabetes signals maps near a gene named KLF14, and that this effect on risk of diabetes is driven by a reduced ability of insulin-sensitive tissues, including muscle and liver, to respond to insulin. We have also shown that, in fat tissue, the same variants near KLF14 have widespread effects on the levels of expression of a wide range of genes, including KLF14 itself. These data are consistent with a model whereby KLF14 acts as a major regulator of events in fat tissue, with these alterations in the levels of KLF14 leading, through as yet unspecified mechanisms, to peripheral insulin resistance and type 2 diabetes.
The overall aim of this research is to define the molecular, cellular and physiological mechanisms which are responsible for the relationship between KLF14 and type 2 diabetes. To do this, we will pursue a number of complementary research strategies which include studies of human genetics and physiology and cellular studies in fat cells.
More specifically, our work aims to:
(a) define the specific sequence variants that are responsible for all of these effects, and how they influence levels of KLF14 within fat cells;
(b) characterise the suite of genes that are turned on and off by KLF14, and understand the consequences of those secondary changes on the function of fat tissue; and
(c) understand how it is that these KLF14-dependent changes in fat tissue lead to changes in the ability of remote tissues (such as muscle and liver) to respond to insulin.
We expect that, by focusing on the role of KLF14 and the ways in which it leads to an increased risk of diabetes, we will gain valuable, generic insights into the mechanisms whereby events in fat have widespread metabolic effects in other tissues. An answer to this question would help us improve our understanding of the connections between obesity and diabetes, an issue of supreme importance given that much of the increase in diabetes prevalence around the world is driven by changes in the amount, distribution and function of fat.
The research provides an opportunity to capitalise on recent discoveries in human genetics to advance understanding of disease biology. In the application, we explain how the biological information generated by this project can be exploited in directly translational studies to define novel approaches for treating, preventing, diagnosing and monitoring type 2 diabetes.
Technical Summary
This major objective of this proposal is to define the molecular, cellular and physiological mechanisms responsible for the association between variants upstream of KLF14 and type 2 diabetes. Our recent work has demonstrated that KLF14 is a master regulator of expression in adipose tissue, and implicate this KLF14-regulated transcriptional network in the genesis of insulin resistance in remote tissues such as muscle and liver.
The research will seek to understand the causes and consequences of altered KLF14 expression using a variety of complementary approaches that include:
(a) human genetics: resequencing, fine-mapping and epigenomic analyses;
(b) integrative physiology: detailed metabolic analyses and genomic studies and their relationship to genotype; and
(c) cellular studies: cellular phenotyping and genomic studies in adipocytes following knockdown and overexpression of KLF14 and selected trans-genes.
The work has four main aims:
(a) To characterise the molecular, cellular and physiological consequences of altered KLF14 expression;
(b) To identify the trans-genes mediating the effect of KLF14 on insulin resistance and type 2 diabetes;
(c) To define the cellular and physiological mechanisms whereby altered KLF14 expression in adipose tissue leads to generalised insulin resistance and T2D;
(d) To characterise the mechanisms whereby common variants upstream of KLF14 influence KLF14 expression.
Our research will, by elucidating the mechanisms linking KLF14 sequence variation to diabetes predisposition, provide valuable, generic, insights into the consequences of adipocyte dysfunction on whole-body physiology. The research can be expected to define novel, causally-validated, targets that are substrates for therapeutic and biomarker development, and the application sets out some of the strategies that we plan to deploy to support those translational goals.
The research will seek to understand the causes and consequences of altered KLF14 expression using a variety of complementary approaches that include:
(a) human genetics: resequencing, fine-mapping and epigenomic analyses;
(b) integrative physiology: detailed metabolic analyses and genomic studies and their relationship to genotype; and
(c) cellular studies: cellular phenotyping and genomic studies in adipocytes following knockdown and overexpression of KLF14 and selected trans-genes.
The work has four main aims:
(a) To characterise the molecular, cellular and physiological consequences of altered KLF14 expression;
(b) To identify the trans-genes mediating the effect of KLF14 on insulin resistance and type 2 diabetes;
(c) To define the cellular and physiological mechanisms whereby altered KLF14 expression in adipose tissue leads to generalised insulin resistance and T2D;
(d) To characterise the mechanisms whereby common variants upstream of KLF14 influence KLF14 expression.
Our research will, by elucidating the mechanisms linking KLF14 sequence variation to diabetes predisposition, provide valuable, generic, insights into the consequences of adipocyte dysfunction on whole-body physiology. The research can be expected to define novel, causally-validated, targets that are substrates for therapeutic and biomarker development, and the application sets out some of the strategies that we plan to deploy to support those translational goals.
Planned Impact
The principal beneficiaries of the research will be:
a) academics in the fields outlined in the "academic beneficiaries" section;
b) industry and biotechnology companies, in a position to exploit the improved biological understanding we seek to provide to develop novel products and services (see below);
c) the public sector (NHS, policy-makers), in the event that the research generates translational advances that provide more cost-effective means of treating and/or preventing diabetes and other insulin-resistance related diseases (e.g. hyperlipidaemias);
d) the wider public, if those translational advances provide more acceptable, more effective strategies for the treatment and prevention of those conditions.
The academic benefits will be manifest through:
a) the generation of new knowledge related to diabetes pathogenesis, which has the potential to contribute to amelioration of the social, economic and personal costs of the "epidemic" of global diabetes;
b) the development of research models and molecules of value for academic research;
c) bolstering of research in human integrative physiology (given concerns about declining expertise);
d) improved training of researchers in the specific areas of research activity, and in the development of cross-disciplinary expertise.
The broader economic and social impact will be manifest through:
a) economic benefits to pharma and biotechnology companies (including "spin-outs" with potential for attracting "inwards" investment) able to exploit actionable translational opportunities with respect to the development of novel therapeutic approaches (building on targets we validate) or clinically-useful biomarkers (building on candidates we identify). Given the scale of the global problem and the inadequacy of current therapeutic and preventative options, the opportunities for wealth creation are substantial;
b) improved effectiveness of public services if the biological insights result in better ways of treating and preventing T2D and related conditions (novel treatments, better diagnostics, improved strategies for stratifying risk and response to interventions);
c) transformation of public policy if the research leads, over time, to improved public health strategies for the prevention of T2D;
d) improved health outcomes (less diabetes-related morbidity and mortality, fewer diabetes complications) if the work leads to effective clinical translation, resulting in further personal, social and economic benefits.
It is of course important to be realistic about the timelines for effective clinical translation: too often expectations in this regard are unrealistic. In practice, the time from "new biology" to "novel treatment" involves years of biological validation, target characterisation, lead molecule optimisation, and clinical evaluation. As is well-known, substantial attrition is typical at each stage. On the positive side:
a) we have recently shown (with the validation of novel biomarkers for monogenic forms of diabetes) that it is possible to move rapidly from genetic discovery to clinical utility, at least where biomarkers are concerned;
b) the massive unmet clinical need and the scale of the global problem with respect to diabetes and insulin resistance will support investments that would not be economic for other diseases;
c) the origins of our research in genetic association data means that the benefits of modulation of the KLF14 network in man have intrinsic causal validation: they also make it possible to explore the whole body effects of such modulation (including potential "on-target" side-effects) through human genetic and physiological studies, helping thereby to minimise attrition;
d) we are well-equipped, via the Target Discovery Institute in Oxford, to initiate high-throughput screens for potential small molecule modulators of this pathway, and to do so in parallel with some of the biological validation described here, thereby expediting progress.
a) academics in the fields outlined in the "academic beneficiaries" section;
b) industry and biotechnology companies, in a position to exploit the improved biological understanding we seek to provide to develop novel products and services (see below);
c) the public sector (NHS, policy-makers), in the event that the research generates translational advances that provide more cost-effective means of treating and/or preventing diabetes and other insulin-resistance related diseases (e.g. hyperlipidaemias);
d) the wider public, if those translational advances provide more acceptable, more effective strategies for the treatment and prevention of those conditions.
The academic benefits will be manifest through:
a) the generation of new knowledge related to diabetes pathogenesis, which has the potential to contribute to amelioration of the social, economic and personal costs of the "epidemic" of global diabetes;
b) the development of research models and molecules of value for academic research;
c) bolstering of research in human integrative physiology (given concerns about declining expertise);
d) improved training of researchers in the specific areas of research activity, and in the development of cross-disciplinary expertise.
The broader economic and social impact will be manifest through:
a) economic benefits to pharma and biotechnology companies (including "spin-outs" with potential for attracting "inwards" investment) able to exploit actionable translational opportunities with respect to the development of novel therapeutic approaches (building on targets we validate) or clinically-useful biomarkers (building on candidates we identify). Given the scale of the global problem and the inadequacy of current therapeutic and preventative options, the opportunities for wealth creation are substantial;
b) improved effectiveness of public services if the biological insights result in better ways of treating and preventing T2D and related conditions (novel treatments, better diagnostics, improved strategies for stratifying risk and response to interventions);
c) transformation of public policy if the research leads, over time, to improved public health strategies for the prevention of T2D;
d) improved health outcomes (less diabetes-related morbidity and mortality, fewer diabetes complications) if the work leads to effective clinical translation, resulting in further personal, social and economic benefits.
It is of course important to be realistic about the timelines for effective clinical translation: too often expectations in this regard are unrealistic. In practice, the time from "new biology" to "novel treatment" involves years of biological validation, target characterisation, lead molecule optimisation, and clinical evaluation. As is well-known, substantial attrition is typical at each stage. On the positive side:
a) we have recently shown (with the validation of novel biomarkers for monogenic forms of diabetes) that it is possible to move rapidly from genetic discovery to clinical utility, at least where biomarkers are concerned;
b) the massive unmet clinical need and the scale of the global problem with respect to diabetes and insulin resistance will support investments that would not be economic for other diseases;
c) the origins of our research in genetic association data means that the benefits of modulation of the KLF14 network in man have intrinsic causal validation: they also make it possible to explore the whole body effects of such modulation (including potential "on-target" side-effects) through human genetic and physiological studies, helping thereby to minimise attrition;
d) we are well-equipped, via the Target Discovery Institute in Oxford, to initiate high-throughput screens for potential small molecule modulators of this pathway, and to do so in parallel with some of the biological validation described here, thereby expediting progress.
Organisations
- University of Oxford (Lead Research Organisation)
- King's College Hospital (Collaboration)
- University of Chicago (Collaboration)
- Novo Nordisk (Collaboration)
- University of California, Los Angeles (UCLA) (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Broad Institute (Collaboration)
- University of Geneva (Collaboration)
- University of Pennsylvania (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- Lund University (Collaboration)
- Sanofi (Collaboration)
- F. Hoffmann-La Roche AG (Collaboration)
- Icahn School of Medicine at Mount Sinai (Collaboration)
- University of Eastern Finland (Collaboration)
Publications
Lu Y
(2016)
New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk.
in Nature communications
Visscher PM
(2017)
10 Years of GWAS Discovery: Biology, Function, and Translation.
in American journal of human genetics
Civelek M
(2017)
Genetic Regulation of Adipose Gene Expression and Cardio-Metabolic Traits.
in American journal of human genetics
Small KS
(2018)
Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on adipocyte size and body composition.
in Nature genetics
Barroso I
(2019)
The Genetic Basis of Metabolic Disease.
in Cell
Loh NY
(2020)
RSPO3 impacts body fat distribution and regulates adipose cell biology in vitro.
in Nature communications
Description | Identification and functional evaluation of genetic and epigenetic determinants of human fat distribution; investigations to understand the cardio-protective effect of lower body adiposity. |
Amount | £779,060 (GBP) |
Funding ID | RG/17/1/32663 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2017 |
End | 06/2022 |
Description | Innovative Medicines Initiative BEATDKD |
Amount | € 15,000,000 (EUR) |
Funding ID | BEATDKD |
Organisation | European Commission |
Department | Innovative Medicines Initiative (IMI) |
Sector | Public |
Country | Belgium |
Start | 09/2017 |
End | 08/2022 |
Description | Innovative Medicines Initiative RHAPSODY |
Amount | € 8,000,000 (EUR) |
Funding ID | 115881 |
Organisation | European Commission |
Department | Innovative Medicines Initiative (IMI) |
Sector | Public |
Country | Belgium |
Start | 04/2016 |
End | 03/2020 |
Description | MRC Experimental Challenges Grant |
Amount | £2,400,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2014 |
End | 08/2018 |
Description | NIH R01 |
Amount | $1,900,000 (USD) |
Funding ID | MH101814 |
Organisation | National Institutes of Health (NIH) |
Department | National Institute of Mental Health (NIMH) |
Sector | Public |
Country | United States |
Start | 09/2013 |
End | 08/2016 |
Description | NIH R01 |
Amount | $2,400,000 (USD) |
Funding ID | DK098032 |
Organisation | National Institutes of Health (NIH) |
Department | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Sector | Public |
Country | United States |
Start | 09/2012 |
End | 08/2016 |
Description | NovoNordisk Funden Immunometabolism |
Amount | 12,000,000 kr. (DKK) |
Funding ID | TRiiC |
Organisation | Novo Nordisk Foundation |
Sector | Charity/Non Profit |
Country | Denmark |
Start | 05/2016 |
End | 04/2020 |
Description | Program grant |
Amount | £1,700,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2015 |
End | 01/2018 |
Description | Project Grant- MRC KLF14 |
Amount | £138,271 (GBP) |
Funding ID | MR/J0106421/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2012 |
End | 01/2015 |
Description | RFP2 call for available datasets |
Amount | $2,400,000 (USD) |
Organisation | Foundation for the National Institutes of Health (FNIH) |
Sector | Charity/Non Profit |
Country | United States |
Start | 03/2016 |
End | 08/2017 |
Description | U01 |
Amount | $1,800,000 (USD) |
Funding ID | DK105535 |
Organisation | National Institutes of Health (NIH) |
Department | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Sector | Public |
Country | United States |
Start | 04/2015 |
End | 03/2019 |
Description | Wellcome Investigator Award |
Amount | £2,250,000 (GBP) |
Funding ID | 212259/Z/18/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2018 |
End | 10/2024 |
Description | Wellcome Trust Strategic Award (WTCHG/WIMM) |
Amount | £2,400,000 (GBP) |
Funding ID | 106130/Z/14/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2015 |
End | 12/2018 |
Title | KLF14 knockout mice |
Description | Global KLF14 knockout mouse |
Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
Provided To Others? | No |
Impact | No recapitulation of the human phenotype in this mouse |
Description | Adipocyte biology (Claussnitzer) |
Organisation | Broad Institute |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | T2D association data |
Collaborator Contribution | Access to adipocyte genomic data |
Impact | none to date |
Start Year | 2018 |
Description | Adipose tissue expression |
Organisation | Icahn School of Medicine at Mount Sinai |
Country | United States |
Sector | Academic/University |
PI Contribution | Collabroation over KLF14 knockout mice |
Collaborator Contribution | Information from human and murine expression studies |
Impact | Information from their proprietary data base |
Start Year | 2012 |
Description | Bo Ahren collaboration |
Organisation | Lund University |
Country | Sweden |
Sector | Academic/University |
PI Contribution | This relates to responding to reviewer comments on our Nature submission |
Collaborator Contribution | Sharing of data from adipose tissue biopsies made by Bo Ahren's group |
Impact | Sharing of data on adipocyte size from adipose biopsies |
Start Year | 2015 |
Description | METSIM |
Organisation | University of California, Los Angeles (UCLA) |
Department | School of Medicine UCLA |
Country | United States |
Sector | Academic/University |
PI Contribution | We collaborate on understanding the mechanisms underlying KLF14 effects on T2D |
Collaborator Contribution | They have contributed data from their studies |
Impact | Collaborative research |
Start Year | 2014 |
Description | METSIM |
Organisation | University of Eastern Finland |
Country | Finland |
Sector | Academic/University |
PI Contribution | We collaborate on understanding the mechanisms underlying KLF14 effects on T2D |
Collaborator Contribution | They have contributed data from their studies |
Impact | Collaborative research |
Start Year | 2014 |
Description | Nobrega collaboration |
Organisation | University of Chicago |
Country | United States |
Sector | Academic/University |
PI Contribution | This is a collaboration to furnish additional data to support revision of our main manuscript which has been reviewed at Nature. |
Collaborator Contribution | KLF14 ChipSeq |
Impact | Marcelo Nobrega is completing studies that will add to our response to reviewers |
Start Year | 2016 |
Description | STEMBANCC |
Organisation | Eli Lilly & Company Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | This is a new IMI collaboration (total funding 53M€ from IMI and in kind) to Oxford and 25 other academic institutions. |
Collaborator Contribution | We will provide clinical material (from patients), characterise stem cell derived tissues derived and manage the diabetes work package |
Impact | Nil to date |
Start Year | 2012 |
Description | STEMBANCC |
Organisation | F. Hoffmann-La Roche AG |
Country | Global |
Sector | Private |
PI Contribution | This is a new IMI collaboration (total funding 53M€ from IMI and in kind) to Oxford and 25 other academic institutions. |
Collaborator Contribution | We will provide clinical material (from patients), characterise stem cell derived tissues derived and manage the diabetes work package |
Impact | Nil to date |
Start Year | 2012 |
Description | STEMBANCC |
Organisation | Novo Nordisk |
Country | Denmark |
Sector | Private |
PI Contribution | This is a new IMI collaboration (total funding 53M€ from IMI and in kind) to Oxford and 25 other academic institutions. |
Collaborator Contribution | We will provide clinical material (from patients), characterise stem cell derived tissues derived and manage the diabetes work package |
Impact | Nil to date |
Start Year | 2012 |
Description | STEMBANCC |
Organisation | Sanofi |
Department | Aventis |
Country | France |
Sector | Private |
PI Contribution | This is a new IMI collaboration (total funding 53M€ from IMI and in kind) to Oxford and 25 other academic institutions. |
Collaborator Contribution | We will provide clinical material (from patients), characterise stem cell derived tissues derived and manage the diabetes work package |
Impact | Nil to date |
Start Year | 2012 |
Description | The MUTHER (Multiple Tissues for Human Expression Resource) Consortium |
Organisation | King's College Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We have contributed to sample preparation, database design and to data analysis |
Collaborator Contribution | it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. |
Impact | We have assembled one of the largest tissue expression banks available and are instituting detailed analysis. Two papers have already been published in high profile journals (Nica, PLoS GENETICS 2010; Small Nature genetics 2011) and further publications are in preparation as of Oct 2011. |
Start Year | 2007 |
Description | The MUTHER (Multiple Tissues for Human Expression Resource) Consortium |
Organisation | The Wellcome Trust Sanger Institute |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | We have contributed to sample preparation, database design and to data analysis |
Collaborator Contribution | it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. |
Impact | We have assembled one of the largest tissue expression banks available and are instituting detailed analysis. Two papers have already been published in high profile journals (Nica, PLoS GENETICS 2010; Small Nature genetics 2011) and further publications are in preparation as of Oct 2011. |
Start Year | 2007 |
Description | The MUTHER (Multiple Tissues for Human Expression Resource) Consortium |
Organisation | University of Geneva |
Country | Switzerland |
Sector | Academic/University |
PI Contribution | We have contributed to sample preparation, database design and to data analysis |
Collaborator Contribution | it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. |
Impact | We have assembled one of the largest tissue expression banks available and are instituting detailed analysis. Two papers have already been published in high profile journals (Nica, PLoS GENETICS 2010; Small Nature genetics 2011) and further publications are in preparation as of Oct 2011. |
Start Year | 2007 |
Description | UCLA collaboration on KLF14 |
Organisation | University of California, Los Angeles (UCLA) |
Department | School of Medicine UCLA |
Country | United States |
Sector | Academic/University |
PI Contribution | Sharing of data regarding role of KLF14 |
Collaborator Contribution | Sharing of data regarding role of KLF14 |
Impact | None so far |
Start Year | 2013 |
Description | UPenn collaboration re KLF14 |
Organisation | University of Pennsylvania |
Country | United States |
Sector | Academic/University |
PI Contribution | Sharing of data regarding role of KLF14 |
Collaborator Contribution | Sharing of data regarding role of KLF14 |
Impact | None as yet |
Start Year | 2015 |
Description | American Society of Nephrology, meeting, New Orleans |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Workshop and talk at ASN 2017 |
Year(s) Of Engagement Activity | 2017 |
Description | Conference on personalised nutrition, Shanghai China |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | International conference on personalised nutrition organised by Chinese colleagues |
Year(s) Of Engagement Activity | 2017 |
Description | East Meets West Conference Hong Kong |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Lecture, debates, discussions about diabetes genetics in East Asia and beyond |
Year(s) Of Engagement Activity | 2016 |
Description | Genomics for Clinicians meeting |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | I gave a presentation at this 4 day workshop on the value of diabetes genetics in genomic medicine |
Year(s) Of Engagement Activity | 2017 |
Description | International Diabetes federation, Abu DHabi |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | PResentation at IDF meeting |
Year(s) Of Engagement Activity | 2017 |
Description | Leena peltonen School of Human Genetics |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Type Of Presentation | Workshop Facilitator |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | I co-organise this meeting which is attended by 20+ PhD students each year. They present to, and interact with 20+ senior academics providing a unique environment Feedback from participants overwhelmingly positive |
Year(s) Of Engagement Activity | 2009,2010,2011,2012,2013,2014,2015,2016 |
Description | Personalised genomics |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Public debate; conference presentations Improved understanding of the issues by the audience |
Year(s) Of Engagement Activity | 2009,2012,2013,2015,2016 |
Description | Scientific presentations and seminars |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Data from these two grants has been presented at a large number of international meetings including American Diabetes Association, American Soc Human Genetics, Genomics of Common Diseases and other meetings (approx 20 a year) Large audiences |
Year(s) Of Engagement Activity | 2012,2013,2015,2016 |
Description | chinese diabetes society, Chongqing |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation to several thousand people at Chinese DIabetes Association |
Year(s) Of Engagement Activity | 2017 |